Journey Medical Corporation to –

SCOTTSDALE, Ariz., May 23, 2022 (GLOBE NEWSWIRE) — Journey Medical Corporation (“Journey Medical”) (NADSAQ:DERM), a commercial-stage pharmaceutical company focused on developing and commercializing pharmaceutical products for the treatment of dermatologicals, today announced that management will be presenting at B. Riley Securities’ 22nd Annual Institutional Investor Conference, to be held May 25-26, 2022 in Beverly Hills, California.

Claude Maraoui, President and CEO, will present a company overview on Thursday, May 26, 2022 at 12:20 p.m. PT and will be available for one-on-one meetings throughout the conference.

About Journey Medical Corporation
Journey Medical Corporation (DERM) (“Journey Medical”) is focused on the identification, acquisition, development and strategic commercialization of innovative and differentiated dermatology products through its effective sales and marketing model. The company currently markets nine products that help treat and cure common skin conditions. The Journey Medical team is comprised of industry experts with extensive experience marketing some of the most successful prescription dermatology brands. Journey Medical is located in Scottsdale, Arizona and was founded by Fortress Biotech, Inc. (FBIO). Journey Medical’s common stock is registered under the Securities Exchange Act of 1934, as amended, and it files periodic reports with the United States Securities and Exchange Commission (“SEC”). For more information about Journey Medical, visit

Forward-looking statements
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. As used below and throughout this press release, the words “we”, “us” and “our” may refer to Journey Medical. Such statements include, but are not limited to, all statements relating to our growth strategy and product development programs and any other statements that are not historical facts. The words “anticipate”, “believe”, “estimate”, “may”, “expect”, “shall”, “could”, “project”, “intend” and similar expressions are generally intended identify forward-looking statements. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could adversely affect our business, results of operations, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, execute and maintain financing and strategic agreements and relationships; risks related to the results of research and development activities; uncertainties related to preclinical and clinical trials; risks relating to the timing of the start and completion of clinical trials, including disruptions that may result from hostilities in Europe; our reliance on third-party vendors; risks related to the COVID-19 outbreak and its potential impact on the ability of our employees and consultants to complete work in a timely manner and our ability to obtain additional financing on favorable terms or not at all; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulations; patents and intellectual property; competition; as well as other risks described in Part I, Item 1A, “Risk Factors,” in our Annual Report on Form 10-K filed March 28, 2022, subsequent reports on Form 10-Q, and our other filings that we perform with the SECOND. We expressly disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based, except where possible. required by law, and we claim safe harbor protection for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

Company details :
Jaclyn Jaffe and Bill Begien
(781) 652-4500
[email protected]

Contact person for media relations:
Tony Plohoros
6 degrees
(908) 591-2839
[email protected]


Luisa D. Fuller